KALV - KalVista Pharmaceuticals GAAP EPS of -$0.84 misses by $0.07
2024-03-11 06:37:30 ET
More on KalVista Pharmaceuticals
- KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data
- KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
- KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement
- KalVista Pharmaceuticals up 16%, prices $160M offering
- Two biotech/pharma stocks to watch - STTK, KALV